"Backyard fire" of Chinese traditional medicine is bound to stop production

Guide: on January 15, the General Administration of food and drug announced that after the follow-up inspection of GMP certification by the food and drug inspection center of the General Administration of food and drug, it was found that Guizhou Zhongtai Biotechnology Co., Ltd did not carry out the simulation filling verification of culture medium in the production cycle of blood products from September to November 2014, did not assess its risk and did not meet the requirements of GMP, so its GMP certificate was withdrawn Enterprises are bound to stop production The General Administration of food and drug requires Guizhou food and drug administration to supervise Guizhou Zhongtai and take effective control measures against potential quality risks to ensure the safety of listed drugs It is reported that in the future drug price reform, the price of blood products is likely to be liberalized, and relevant companies will surely benefit at that time At this time, the withdrawal of GMP certificate of Chinese traditional medicine company is undoubtedly bad news Guizhou Zhongtai is a subsidiary company of Chinese traditional medicine, mainly engaged in the research and development, production and sales of blood products The company owns production capacity of albumin and coagulation factor It has a long history with Chinese traditional medicine According to the announcement of Chinese traditional medicine, on December 22, 2011, Guizhou Zhongtai, Guangdong globegroup and Henan Xintai entered into an investment agreement Guangdong global will invest 153 million yuan in Guizhou Zhongtai at the cost of cash, accounting for 51% of its shares Guangdong universal is now a wholly-owned subsidiary of traditional Chinese medicine "Guizhou Zhongtai has a bright business prospect, is engaged in the development of biomedicine, and the investment matters create synergy benefits for the group's pharmaceutical business in China." At the time of acquisition in 2011, China traditional Chinese medicine said that, however, Guizhou zhongtaidang had not started production at that time, and had not generated any gains and losses of 13.8 million yuan from 2009 to December 31, 2010 　　 Senior Chinese medicine executives have full confidence in Guizhou Zhongtai Xu Tiefeng, executive vice chairman of Yingtian Pharmaceutical Group, and Yang Bin, executive president of Yingtian Pharmaceutical Group (now executive president of traditional Chinese Medicine) believe that Yingtian pharmaceutical's joint venture with Guizhou Zhongtai means that Yingtian Pharmaceutical Group has officially entered the field of biopharmaceutical industry As a new strategic industry in the 21st century, biopharmaceutical will provide development for Yingtian Pharmaceutical Group Strong driving force However, the performance of Guizhou Zhongtai is difficult to satisfy the Chinese traditional medicine In the first half of 2013, the operating revenue of Guizhou Zhongtai was 7.86 million yuan and the loss was 9.23 million yuan Chinese herbal medicine once wanted to sell it On August 26, 2013, Chinese herbal medicine announced that it would sell 51% of Guizhou Zhongtai's shares of 100 million yuan There are four reasons for the sale of Guizhou Zhongtai: first, Guizhou Zhongtai originally planned to obtain all the approvals for the products on December 31, 2012, but has not yet obtained them Second, Guizhou Zhongtai business is still in the early stage of development and is not expected to make significant contributions to the group in the next few years Third, Guizhou Zhongtai expects that it will need to inject a large amount of funds to make its operation reach a considerable scale 4 The main products of Guizhou Zhongtai do not conform to the commodity positioning of traditional Chinese medicine and drugs of the group However, on March 6, 2014, Chinese herbal medicine suddenly changed its mind and terminated the agreement with Foshan Shunde Hefeng Investment Co., Ltd to sell Guizhou Zhongtai "The business of Guizhou Zhongtai will improve significantly in the foreseeable future, and it is more in the overall interests of shareholders to continue to hold Guizhou Zhongtai than to complete the sale transaction." Chinese traditional medicine.